Angiocrine Bioscience Company

Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
Technology: Bioengineering
Industry: Cell Therapy, Private
Headquarters: New York, New York, United States
Founded Date: 2012-01-01
Employees Number: 11-50
Funding Status: Private Equity
Investors Number: 1
Total Funding: 77121795
Estimated Revenue: $1M to $10M
Last Funding Date: 2022-12-19
Last Funding Type: Grant

Visit Website
info@angiocrinebio.com
https://www.twitter.com/angiocrine
Register and Claim Ownership